A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04853576 |
Recruitment Status :
Recruiting
First Posted : April 21, 2021
Last Update Posted : February 1, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sickle Cell Disease Hemoglobinopathies | Genetic: EDIT-301 | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 45 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease |
Actual Study Start Date : | May 4, 2021 |
Estimated Primary Completion Date : | August 2025 |
Estimated Study Completion Date : | August 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: EDIT-301
EDIT-301 (autologous gene edited (CD)34+ hematopoietic stem cells) will be administered as a one-time intravenous infusion.
|
Genetic: EDIT-301
Administered by IV infusion after myeloablative conditioning with busulfan.
Other Names:
|
- Proportion of subjects achieving complete resolution of severe vaso-occlusive events (VOEs) [ Time Frame: up to 2 years post EDIT-301 infusion ]
- Proportion of subjects achieving complete resolution of VOEs [ Time Frame: up to 2 years post EDIT-301 infusion ]
- Proportion of subjects with 90% reduction in annualized rate of severe VOE compared to pre-treatment period [ Time Frame: up to 2 years post EDIT-301 infusion ]
- Proportion of subjects with 75% reduction in annualized rate of severe VOE compared to pre-treatment period [ Time Frame: up to 2 years post EDIT-301 infusion ]
- Proportion of subjects with 50% reduction in annualized rate of severe VOE compared to pre-treatment period [ Time Frame: up to 2 years post EDIT-301 infusion ]
- Difference (pre-treatment vs. post-treatment) in annualized rates of severe VOEs [ Time Frame: up to 2 years post EDIT-301 infusion ]
- Difference (pre-treatment vs. post-treatment) in annualized rate of hospitalization for severe VOEs [ Time Frame: up to 2 years post EDIT-301 infusion ]
- Proportion of subjects with sustained HbF ≥ 20% (HbF/Hb) compared with baseline [ Time Frame: up to 2 years post EDIT-301 infusion ]
- Proportion of subjects with mean HbF ≥ 30% (HbF/Hb) compared with baseline [ Time Frame: up to 2 years post EDIT-301 infusion ]
- Proportion of subjects with mean total Hb ≥ 10 g/dL compared with baseline [ Time Frame: up to 2 years post EDIT-301 infusion ]
- Proportion of subjects with mean total Hb increase from baseline of ≥ 2 g/dL [ Time Frame: up to 2 years post EDIT-301 infusion ]
- Difference (pre-treatment versus post-treatment) in annualized number of units of pRBC transfused for SCD-related indications [ Time Frame: up to 2 years post EDIT-301 infusion ]
- Change from baseline in HbF concentration (g/dL) [ Time Frame: up to 2 years post EDIT-301 infusion ]
- Change from baseline in total Hb concentration (g/dL) [ Time Frame: up to 2 years post EDIT-301 infusion ]
- Change from baseline in markers of hemolysis (absolute reticulocyte count, indirect bilirubin, lactate dehydrogenase, haptoglobin) [ Time Frame: up to 2 years post EDIT-301 infusion ]
- Time to neutrophil engraftment (the first day in which 3 consecutive absolute neutrophil count (ANC) ≥ 0.5 x 109/L laboratory values obtained on different days) [ Time Frame: up to 24 months after EDIT-301 infusion ]
- Time to platelet engraftment (the first day in which 3 consecutive platelets ≥ 50 x 109/L laboratory values obtained for at least 7 days following the last platelet transfusion and 10 days following any administration of thrombopoietin (TPO) mimetics) [ Time Frame: up to 24 months after EDIT-301 infusion ]
- Frequency and severity of adverse events (AEs) [ Time Frame: up to 24 months post EDIT-301 infusion ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 50 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
Diagnosis of severe sickle cell disease as defined by:
- Documented SCD genotype (βS/βS, βS/β0, βS/β+, or others) and
- History of at least two severe vaso-occlusive events per year requiring medical attention despite hydroxyurea or other supportive care measures in the two year-period prior to provision of informed consent or assent, as applicable
Karnofsky (for subjects >16 years of age) or Lansky (for subjects ≤ 16 years of age) Performance Status ≥ 80%
Normal transcranial doppler velocity in subjects 16 years of age or younger
Key Exclusion Criteria:
- Available 10/10 HLA-matched related donor
- Prior HSCT or contraindications to autologous HSCT
- Any contraindications to the use of plerixafor during the mobilization of hematopoietic stem cells (HSCs) and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients
- Unable to receive red blood cell (RBC) transfusion for any reason
- Unable or unwilling to comply with standard of care changes in background medical treatment in preparation of, during, or following HSCT, including and not limited to discontinuation of hydroxyurea, voxelotor, crizanlizumab, or L-glutamine
- Any history of severe cerebral vasculopathy
- Inadequate end organ function
- Advanced liver disease
- Any prior or current malignancy or immunodeficiency disorder
- Immediate family member with a known or suspected Familial Cancer Syndrome
- Clinically significant and active bacterial, viral, fungal, or parasitic infection
Other protocol defined inclusion/exclusion criteria may apply
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04853576
Contact: Editas Medicine's Clinical Trial Team | 617-401-9007 | Patients@editasmed.com |
Responsible Party: | Editas Medicine, Inc. |
ClinicalTrials.gov Identifier: | NCT04853576 |
Other Study ID Numbers: |
EM-SCD-301-001 |
First Posted: | April 21, 2021 Key Record Dates |
Last Update Posted: | February 1, 2024 |
Last Verified: | January 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Anemia Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Genetic Diseases, Inborn |
Cell Disorders, Sickle HbS Disease Sickling Disorder Due to Hemoglobin S Hematologic Diseases |
Anemia, Sickle Cell Hemoglobinopathies Anemia, Hemolytic, Congenital Anemia, Hemolytic |
Anemia Hematologic Diseases Genetic Diseases, Inborn |